Hormonal Contraception and the Informed Consent*

Abstract

Since the 1960s, hormonal contraceptives have become the most commonly used method of pregnancy prevention in the United States and the world. Oral contraceptives are used by a large percentage of women, including Christian women. There are known health risks to women demonstrated in research published since Pope Paul VI’s prophetic encyclical Humanae vitae in 1968. These risks include venous thrombosis, cardiovascular risks, and an increased risk of cancer. These risks are medically recognized with continued scientific debate on the degree. The risks are significantly increased with preexisting conditions and in certain demographic groups. Discussing known and potential treatment risks is a standard that is both accepted by the medical community and is increasingly expected by patients. This discussion can be accomplished by the mechanism and principle of informed consent. Depending on the circumstances, abstinence or fertility awareness-based methods (FABMs) should be presented to patients. FABMs are licit, safe, and effective methods of pregnancy prevention. Informed consent is the most effective means of providing patients with pertinent information on the significant risks of contraception.

Summary:

This article discusses the use of the informed consent to provide patients with information on the medical and ethical risks of oral contraceptives. FABMs and abstinence are presented as effective, safe, and licit preferences to oral contraceptives. Discussing known and potential treatment risks is accepted by the medical community and expected by patients (shared decision making). The authors discuss the historical context of Pope Paul VI’s encyclical Humanae vitae in relationship to the development and rapid adoption of oral contraceptives.

Keywords

Breast cancer Fertility awareness–based method Informed consent Natural family planning Oral contraception Shared decision making Venous thrombosis

Get full access to this article

View all access options for this article.

References

Arevalo

Jennings

Sinai

. 2002. “Efficacy of a New Method of Family Planning: The Standard Days Method.” Contraception 65: 333–38.

Arevalo

Jennings

Nikula

Sinai

. 2004. “Efficacy of the New Two Day Method of Natural Family Planning.” Fertility and Sterility 82, no. 4: 885–92.

Baerwald

A. R.

Pierson

R. A.

. 2004. “Ovarian Follicular Development during the Use of Oral Contraception: A Review.” Journal of Obstetrics and Gynaecology Canada 26, no. 1: 19–24.

Baeten

J. M.

Benki

Chohan

Lavreys

McClelland

R. S.

Mandaliya

Ndinya-Achola

J. O.

Jaoko

Overbaugh

. 2007. “Hormonal Contraceptive Use, Herpes Simplex Virus Infection, and Risk of HIV Acquisition among Kenyan Women.” AIDS 21, no. 13: 1771–77.

Beaber

E. F.

Buist

D. S.

Barlow

W. E.

Malone

K. E.

Reed

S. D.

C. I.

. 2014. “Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20–49 Years of Age.” Cancer Research 74, no. 15: 4078–89.

Blanco-Molina

Monreal

. 2010, February. “Venous Thromboembolism in Women Taking Hormonal Contraceptives.” Expert Review of Cardiovascular Therapy 8, no. 2: 211–5.

Canterbury v. Spence. 1972, 464 F.2d 772. Washington, DC: US Court of Appeals for the District of Columbia.

Cogliano

V. Y.

Cogliano

Grosse

Baan

Straif

Secretan

F. B.

Ghissassi

E. I.

. 2005. “Carcinogenicity of Combined Oestrogen-Progesterone Contraceptives and Menopausal Treatment.” Lancet Oncology 6:552–53.

Collaborative Group on Hormonal Factors in Breast Cancer. 1996. “Breast Cancer and Hormonal Contraceptives: Collaborative Reanalysis of Individual Data on 53,297 Women with Breast Cancer and 100,239 Women without Breast Cancer from 54 Epidemiological Studies.” Lancet 347, no. 9017: 1713–27.

10.

Coulter

1997. “Partnership with Patients: The Pros and Cons of Shared Clinical Decision-Making.” Journal of Health Services Research & Policy 2, no. 2: 112–21.

11.

de Bastos

Stegeman

B. H.

Rosendaal

F. R.

Van Hylckama Vlieg

Helmerhorst

F. M.

Stijnen

Dekkers

O. M.

. 2014. “Combined Oral Contraceptives: Venous Thrombosis.” The Cochrane Database of Systematic Reviews 3:CD010813.

12.

Dolle

J. M.

Daling

J. R.

White

Brinton

L. A.

Doody

D. R.

Porter

P. L.

Malone

K. E.

. 2009. “Risk Factors for Triple Negative Breast Cancer in Women under the Age of 45 Years.” Cancer Epidemiology Biomarkers & Prevention 18, no. 4: 1157–66.

13.

Entwistle

V. A.

Carter

S. M.

Cribb

McCaffery

. 2010. “Supporting Patient Autonomy: The Importance of Clinician-Patient Relationships.” Journal of General Internal Medicine 25, no. 7: 741–45.

14.

Fehring

R. J.

Raviele

Schneider

. 2004. “A Comparison of the Fertile Phase as Determined by the Clearplan Easy Fertility Monitor and Self-assessment of Cervical Mucus.” Contraception 69:9–14.

15.

Giannitrapani

Soresi

La Spada

Cervello

D’Alessandro

, and Montalto

. 2006, November. “Sex Hormones and Risk of Liver Tumor.” Annals of the New York Academy of Sciences 1089: 228–36.

16.

Goldscheider

Mosher

W. D.

. 1991. “Patterns of Contraceptive Use in the United States: The Importance of Religious Factors.” Studies in Family Planning 22, no. 2: 102–15.

17.

Grosse

Baan

Straif

Secretan

El Ghissassi

Bouvard

Benbrahim-Tallaa

Guha

Galichet

Cogliano

. and WHO International Agency for Research on Cancer Monograph Working Group. 2009. “A Review of Human Carcinogens—Part A: Pharmaceuticals.” Lancet Oncology 10, no. 1: 13–14.

18.

Hall

Daniel E.

Prochazka Allen

Fink

A. S.

. 2012. “Informed Consent for Clinical Treatment.” Canadian Medical Association Journal 184, no. 5: 533–40.

19.

Hilger

David J.

2015. “Contraception and Informed Consent.” Ethics & Medics 40, no. 12: 1–4.

20.

Hilgers

T. W.

Stanford

J. B.

. 1998. “Creighton Model NaProEducation Technology for Avoiding Pregnancy. Use Effectiveness.” Journal of Reproductive Medicine 43, no. 6: 495–502.

21.

International Collaboration of Epidemiological Studies of Cervical Cancer. 2007. “Cervical Cancer and Hormonal Contraceptives: Collaborative Reanalysis of Individual Data for 16,573 Women with Cervical Cancer and 35,509 Women Without Cervical Cancer from 24 Epidemiological Studies.” The Lancet 370, no. 9599: 1609–21.

22.

John Paul II

Pope

. 1981. Familiaris consortio (The Role of the Christian Family in the Modern World). http://w2.vatican.va/content/john-paul-ii/en/apost_exhortations/documents/hf_jp-ii_exh_19811122_familiaris-consortio.html.

23.

John Paul II

Pope

. 2006. Man and Woman He Created Them. A Theology of the Body, trans. Waldstein

Michael

. Boston, MA: Pauline Books and Media.

24.

Johnson

R. H.

Chien

F. L.

Bleyer

. 2013. “Incidence of Breast Cancer with Distant Involvement among Women in the United States, 1996 to 2009.” Journal of the American Medical Association 309:800–05.

25.

Junod

S. W.

Marks

. 2002. “Women’s Trials: The Approval of the First Oral Contraceptive Pill in the United States and Great Britain.” Journal of the History of Medicine and Allied Sciences 57, no. 2: 117–60.

26.

Kahlenborn

Modugno

Potter

D. M.

Severs

W. B.

. 2006. “Oral Contraceptive Use as a Risk Factor for Premenopausal Breast Cancer: A Meta-analysis.” Mayo Clinic Proceedings 81, no. 10: 1290–302.

27.

Kemmeren

J. M.

Tanis

B. C.

van den Bosch

M. A.

Bollen

E. L.

Helmerhorst

F. M.

van der Graaf

Rosendaal

F. R.

Algra

. 2002, May. “Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study: Oral Contraceptives and the Risk of Ischemic Stroke.” Stroke 33, no. 5: 1202–08.

28.

Larimore

W. L.

Stanford

J. B.

. 2000. “Postfertilization Effects of Oral Contraceptives and Their Relationship to Informed Consent.” Archives of Family Medicine 9, no. 2: 126–33.

29.

Martinelli

Sacchi

Landi

Taioli

Duca

Mannucci

P. M.

. 1998. “High Risk of Cerebral-Vein Thrombosis in Carriers of a Prothrombin-Gene Mutation and in Users of Contraceptives.” New England Journal of Medicine 338, no. 25: 1793–97.

30.

McCormack

V. A.

dos Santos Silva

. 2006. “Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis.” Cancer Epidemiology Biomarkers & Prevention 15, no. 6: 1159–69.

31.

Mercedes

A. Wilson

. 2002. “The Practice of Natural Family Planning versus the Use of Artificial Birth Control: Family, Sexual, and Moral Issues.” Catholic Social Science Review 7:1–20.

32.

Mørch

Lina

Skovlund

C. W.

Hannaford

P. C.

Iversen

Fielding

Lidegaard

Ø.

. 2017. “Contemporary Hormonal Contraception and the Risk of Breast Cancer.” New England Journal of Medicine 377, no. 23: 2228–39.

33.

Moreno

2002. “Effect of Oral Contraceptives on Risk of Cervical Cancer in Women with Human Papillomavirus Infection: The IARC Multicentric Case-Control Study.” Lancet 359, no. 9312: 1085–92.

34.

Mosher

W. D.

Martinez

G. M.

Chandra

Abma

J. C.

Willson

S. J.

. 2004, December. “Use of Contraception and Use of Family Planning Services in the United States 1982–2002.” Advance Data 350: 1–36.

35.

Pallone

S. R.

Bergus

G. R.

. 2009. “Fertility Awareness-Based Methods: Another Option for Family Planning.” Journal of the American Board of Family Medicine 22, no. 2: 147–57.

36.

Patrick

T. J.

Carson

G. V.

Allen

M. C.

. 2008. “Medical Informed Consent for Physicians.” Mayo Clinic Proceedings 83, no. 3: 313–19.

37.

Paul VI

Pope

. 1968. Humanae vitae. http://w2.vatican.va/content/paul-vi/en/encyclicals/documents/hf_p-vi_enc_25071968_humanae-vitae.html.

38.

Rossouw

J. E.

Anderson

G. L.

Prentice

R. L.

LaCroix

A. Z.

Kooperberg

Stefanick

M. L.

Jackson

R. D.

Beresford

S. A.

Howard

B. V.

Johnson

K. C.

Kotchen

J. M.

Ockene

, and Writing Group for the Women’s Health Initiative Investigators. 2002. “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial.” Journal of the American Medical Association 288, no. 3: 321–33.

39.

Ryder

R. E.

1993. “Natural Family Planning: Effective Birth Control Supported by the Catholic Church.” British Medical Journal 307, no. 6906: 723–26.

40.

Shannon

William H.

1970. The Lively Debate: Response to Humanae vitae. New York: Sheed & Ward.

41.

Stanford

J. B.

Lemaire

J. C.

Fox

. 1994. “Interest in Natural Family Planning among Female Family Practice Patients.” Family Practice Research Journal 14, no. 3: 237–49.

42.

Stanford

J. B.

Lemaire

J. C.

Thurman

P. B.

. 1998. “Women’s Interest in Natural Family Planning.” Journal of Family Practice 46, no. 1: 65–71.

43.

Supreme Court of Iowa. Pauscher v. Iowa Methodist Medical Center, et al. 1987. Des Moines, Iowa. 408 NW 2d 355 Iowa Supreme Court.

44.

Tanis

B. C.

Rosendaal

F. R.

. 2003. “Venous and Arterial Thrombosis during Oral Contraceptive Use: Risks and Risk Factors.” Seminars in Vascular Medicine 3, no. 1: 69–84.

45.

Trussell

2011. “Contraceptive Failure in the United States.” Contraception 83, no. 5: 397–404.

46.

USCCB (US Conference of Catholic Bishops). Ethical and Religious Directives for Catholic Health Care Services, 5th ed. Washington, DC: USCCB. http://www.usccb.org/issues-and-action/human-life-and-dignity/health-care/upload/Ethical-Religious-Directives-Catholic-Health-Care-Services-fifth-edition-2009.pdf.

47.

Weller

Davis

. 2002. “Condom Effectiveness in Reducing Heterosexual HIV Transmission.” Cochrane Database System Review 1, no. 2002: CD003255.

48.

Will

J. F.

2011. “A Brief Historical and Theoretical Perspective on Patient Autonomy and Medical Decision Making: Part 1: The Beneficence Model.” Chest 139, no. 3: 669–73.